索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]牛绍乾,张晓晴,汪雁博,等.冠状动脉支架植入术后抗血小板策略的研究进展[J].国际心血管病杂志,2021,01:9-12.
点击复制

冠状动脉支架植入术后抗血小板策略的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2021年01期
页码:
9-12
栏目:
综述
出版日期:
2021-01-20

文章信息/Info

Title:
-
作者:
牛绍乾; 张晓晴; 汪雁博; 李伟; 傅向华
050000 石家庄,河北医科大学第二医院心内五科(牛绍乾,汪雁博,李伟,傅向华)河北省人民医院心内科(张晓晴)
Author(s):
-
关键词:
经皮冠状动脉介入术;  双联抗血小板;  单药治疗
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2021.01.003
文献标识码:
-
摘要:
对于经皮冠状动脉介入术(PCI)后患者,国内外指南均首选推荐12个月的双联抗血小板治疗(DAPT)方案,但由于患者对抗血小板药物治疗反应多样,如何选择适宜的个体化DAPT方案有待进一步研究。该文介绍近年来不同抗血小板药物策略的临床试验获益情况,以期为临床治疗提供一定参考
Abstract:
-

参考文献/References

[1] Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC)[J]. Eur Heart J, 2018, 39(2):119-177.
[2] Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2(Second International Study of Infarct Survival)Collaborative Group[J]. Lancet,1988, 2(8607):349-360.
[3] Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials[J]. Lancet, 2009, 373(9678):1849-1860.
[4] 国家卫生计生委合理用药专家委员会.急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版), 2019, 11(01):40-65.
[5] James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12)receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes(PLATO)trial[J]. Am Heart J, 2009, 157(4):599-605.
[6] Kim MC, Jeong MH, Sim DS, et al. Optimal timing of percutaneous coronary intervention in patients with non-ST-segment elevation myocardial infarction complicated by acute decompensated heart failure(from the Korea acute myocardial infarction registry-national institutes of health[KAMIR-NIH])[J]. Am J Cardiol, 2018, 121(11):1285-1292.
[7] Goto S, Huang CH, Park SJ, et al. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome—randomized, double-blind, phase Ⅲ PHILO study[J]. Circ J, 2015, 79(11):2452-2460.
[8] Sun Y, Li C, Zhang L, et al. Clinical outcomes after ticagrelor and clopidogrel in Chinese post-stented patients[J]. Atherosclerosis, 2019, 290:52-58.
[9] Ma S, Li Z, Yu P, et al. Efficacy and safety of potent oral P2Y(12)inhibitors in medically managed ACS patients: a meta-analysis[J]. Cardiovasc Drugs Ther, 2020, 34(2):199-208.
[10] Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review[J]. JAMA, 2007, 297(18):2018-2024.
[11] Jolly SS, Pogue J, Haladyn K, et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study[J]. Eur Heart J, 2009, 30(8):900-907.
[12] Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes(CURRENT-OASIS 7): a randomised factorial trial[J]. Lancet, 2010, 376(9748):1233-1243.
[13] Li J, Sheng Z, Tan Y, et al. Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients: insights from the TIFU(Ticagrelor in Fuwai Hospital)study[J]. Platelets, 2019, 23:1-7.
[14] Mega JL, Hochholzer W, Frelinger AR, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease[J]. JAMA, 2011, 306(20):2221-2228.
[15] Hart MR, Garrison LJ, Doyle DL, et al. Projected cost-effectiveness for 2 gene-drug pairs using a multigene panel for patients undergoing percutaneous coronary intervention[J]. Value Health, 2019, 22(11):1231-1239.
[16] Bonaca MP, Storey RF, Theroux P, et al. Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54[J]. J Am Coll Cardiol, 2017, 70(11):1368-1375.
[17] Choi KN, Jin HY, Shin HC, et al. Comparison of the antiplatelet effects of once and twice daily low-dose ticagrelor and clopidogrel after percutaneous coronary intervention[J]. Am J Cardiol, 2017, 120(2):201-206.
[18] Lee YJ, Kim H, Choi J, et al. Evaluation of pharmacokinetic, pharmacodynamic, efficacy, and safety data of low-dose ticagrelor versus standard dose in East Asians: a systematic review[J]. Ther Clin Risk Manag, 2018, 14:83-93.
[19] Tanzilli G, Greco C, Pelliccia F, et al. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation(from the TYCOON [two-year ClOpidOgrel need] study)[J]. Am J Cardiol, 2009, 104(10):1357-1361.
[20] Yin SH, Xu P, Wang B, et al. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis[J]. BMJ, 2019, 365:l2222.
[21] Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease[J]. J Am Coll Cardiol, 2016, 67(23):2719-2728.
[22] Thomas MR, Angiolillo DJ, Bonaca MP, et al. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status[J]. Thromb Haemost, 2017, 117(5):940-947.
[23] Kedhi E, Fabris E, van der Ent M, et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction(DAPT-STEMI): randomised, multicentre, non-inferiority trial[J]. BMJ, 2018, 363:k3793.
[24] De Luca G, Damen SA, Camaro C, et al. Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent(REDUCE trial)[J]. EuroIntervention, 2019, 15(11):e990-e998
[25] Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial[J]. Lancet, 2018, 392(10151):940-949.
[26] Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI[J]. JAMA, 2019, 321(24):2414-2427.
[27] Kim B, Hong S, Cho Y, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome[J]. JAMA, 2020, 323(23):2407-2416.

备注/Memo

备注/Memo:
通信作者:傅向华,E-mail:fuxh999@163.com
更新日期/Last Update: 2021-01-20